🍁 Golden Autumn, Big Prizes Await!
Gate Square Growth Points Lucky Draw Carnival Round 1️⃣ 3️⃣ Is Now Live!
🎁 Prize pool over $15,000+, iPhone 17 Pro Max, Gate exclusive Merch and more awaits you!
👉 Draw now: https://www.gate.com/activities/pointprize/?now_period=13&refUid=13129053
💡 How to earn more Growth Points for extra chances?
1️⃣ Go to [Square], tap the icon next to your avatar to enter [Community Center]
2️⃣ Complete daily tasks like posting, commenting, liking, and chatting to rack up points!
🍀 100% win rate — you’ll never walk away empty-handed. Try your luck today!
Details: ht
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.